Development of hyperactivity and anxiety responses in dopamine transporter-deficient mice

Developmental Neuroscience

Volumn 34, Issue 2-3, 2012, Pages 250-257

  Carpenter, Alex C ^a   Saborido, Tommy P ^a   Stanwood, Gregg D ^a,b  

^a Department of Pharmacology ^*  (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Cognition; Development; Dopamine transporter; Knockout mice; Locomotion; Memory; Mouse; postnatal; Striatum

Indexed keywords

DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR GENETICS; CONTROLLED STUDY; GENE INACTIVATION; HAPLOINSUFFICIENCY; HYPERACTIVITY; KNOCKOUT MOUSE; LIGHT DARK CYCLE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WORKING MEMORY;

ANIMALS; ANXIETY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HYPERKINESIS; MEMORY, SHORT-TERM; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; SPATIAL BEHAVIOR;

EID: 84866295257     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000336824     Document Type: Article

References (54)

1. Medvedev IO, Gainetdinov RR, Sotnikova TD, Bohn LM, Caron MG, Dykstra LA: Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology (Berl) 2005; 180: 408-413.
2. Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG: Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets 2006; 5: 45-56.
3. Gainetdinov RR, Caron MG: Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 2003; 43: 261-284.
4. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
5. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG: Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 1998; 95: 4029-4034.
6. Bosse R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR, Wetsel WC, Missale C, Caron MG: Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 1997; 19: 127-138.
7. Li B, Arime Y, Hall FS, Uhl GR, Sora I: Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice. Eur J Pharmacol 2010; 628: 104-107.
8. Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M: Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 2003; 116: 1123-1130.
9. Sotnikova TD, Caron MG, Gainetdinov RR: DDD mice, a novel acute mouse model of Parkinson's disease. Neurology 2006; 67:S12-S17.
10. Lewis DA, Levitt P: Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002; 25: 409-432.
11. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
12. Raedler TJ, Knable MB, Weinberger DR: Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 1998; 8: 157-161.
13. Rice D, Barone S Jr: Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ Health Perspect 2000; 108(suppl 3):511-533.
14. Frederick AL, Stanwood GD: Drugs, biogenic amine targets and the developing brain. Dev Neurosci 2009; 31: 7-22.
15. Jones LB, Stanwood GD, Reinoso BS, Washington RA, Wang HY, Friedman E, Levitt P: In utero cocaine-induced dysfunction of dopamine D 1 receptor signaling and abnormal differentiation of cerebral cortical neurons. J Neurosci 2000; 20: 4606-4614.
16. Stanwood GD, Levitt P: Prenatal exposure tococaine produces unique developmental and long-term adaptive changes in dopamine D 1 receptor activity and subcellular distribution. J Neurosci 2007; 27: 152-157.
17. Stanwood GD, Washington RA, Levitt P: Identification of a sensitive period of prenatal cocaine exposure that alters the development of the anterior cingulate cortex. Cereb Cortex 2001; 11: 430-440.
18. Stanwood GD, Washington RA, Shumsky JS, Levitt P: Prenatal cocaine exposure produces consistent developmental alterations in dopamine- rich regions of the cerebral cortex. Neuroscience 2001; 106: 5-14.
19. Thompson BL, Stanwood GD, Levitt P: Specificity of prenatal cocaine exposure effects on cortical interneurons is independent from dopamine D 1 receptor co-localization. J Chem Neuroanat 2010; 39: 228-234.
20. Wang HY, Runyan S, Yadin E, Friedman E: Prenatal exposure to cocaine selectively reduces D 1 dopamine receptor-mediated activation of striatal Gs proteins. J Pharmacol Exp Ther 1995; 273: 492-498.
21. Stanwood GD, Levitt P: Repeated i.v. cocaine exposure produces long-lasting behavioral sensitization in pregnant adults, but behavioral tolerance in their offspring. Neuroscience 2003; 122: 579-583.
22. Romano AG, Kachelries WJ, Simansky KJ, Harvey JA: Intrauterine exposure to cocaine produces a modality-specific acceleration of classical conditioning in adult rabbits. Pharmacol Biochem Behav 1995; 52: 415-420.
23. Thompson BL, Levitt P, Stanwood GD: Prenatal cocaine exposure specifically alters spontaneous alternation behavior. Behav Brain Res 2005; 164: 107-116.
24. Dumartin B, Jaber M, Gonon F, Caron MG, Giros B, Bloch B: Dopamine tone regulates D 1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proc Natl Acad Sci USA 2000; 97: 1879-1884.
25. Zhang X, Bearer EL, Boulat B, Hall FS, Uhl GR, Jacobs RE: Altered neurocircuitry in the dopamine transporter knockout mouse brain. PLoS One 2010; 5:e11506.
26. Stanwood GD, Parlaman JP, Levitt P: Anatomical abnormalities in dopaminoceptive regions of the cerebral cortex of dopamine D 1 receptor mutant mice. J Comp Neurol 2005; 487: 270-282.
27. Morice E, Denis C, Giros B, Nosten-Bertrand M: Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur J Neurosci 2004; 20: 120-126.
28. Braun AA, Skelton MR, Vorhees CV, Williams MT: Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: Effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav 2011; 97: 406-415.
29. Gustin RM, Shonesy BC, Robinson SL, Rentz TJ, Baucum AJ 2nd, Jalan-Sakrikar N, Winder DG, Stanwood GD, Colbran RJ: Loss of Thr286 phosphorylation disrupts synaptic caMKIIalpha targeting, NMDAR activity and behavior in pre-adolescent mice. Mol Cell Neurosci 2011; 47: 286-292.
30. Lalonde R: The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 2002; 26: 91-104.
31. Pogorelov VM, Rodriguiz RM, Insco ML, Caron MG, Wetsel WC: Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology 2005; 30: 1818-1831.
32. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR: Cocaine reward models: Conditioned place preference can be established in dopamineand in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998; 95: 7699- 7704.
33. Hall FS, Li XF, Randall-Thompson J, Sora I, Murphy DL, Lesch KP, Caron M, Uhl GR: Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice. Neuroscience 2009; 162: 870-880.
34. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG: Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA 2001; 98: 11047-11054.
35. Tian YH, Baek JH, Lee SY, Jang CG: Prenatal and postnatal exposure to bisphenol a inducesanxiolytic behaviors and cognitive deficits in mice. Synapse 2010; 64: 432-439.
36. Catania EH, Pimenta A, Levitt P: Genetic deletion of Lsamp causes exaggerated behavioral activation in novel environments. Behav Brain Res 2008; 188: 380-390.
37. Biederman J: Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005; 57: 1215-1220.
38. Spencer TJ: Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs 2009; 23(suppl 1):9-20.
39. Taurines R, Schmitt J, Renner T, Conner AC, Warnke A, Romanos M: Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord 2010; 2: 267-289.
40. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD: Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 2005; 49: 724.
41. Hughes RN: The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev 2004; 28: 497-505.
42. Xu TX, Sotnikova TD, Liang C, Zhang J, Jung JU, Spealman RD, Gainetdinov RR, Yao WD: Hyperdopaminergic tone erodes prefrontal long-term potential via a D 2 receptoroperated protein phosphatase gate. J Neurosci 2009; 29: 14086-14099.
43. Cyr M, Caron MG, Johnson GA, Laakso A: Magnetic resonance imaging at microscopic resolution reveals subtle morphological changes in a mouse model of dopaminergic hyperfunction. Neuroimage 2005; 26: 83-90.
44. Bhide PG: Dopamine, cocaine and the development of cerebral cortical cytoarchitecture: A review of current concepts. Semin Cell Dev Biol 2009; 20: 395-402.
45. Ren JQ, Jiang Y, Wang Z, McCarthy D, Rajadhyaksha AM, Tropea TF, Kosofsky BE, Bhide PG: Prenatal L -dopa exposure produces lasting changes in brain dopamine content, cocaine-induced dopamine release and cocaine conditioned place preference. Neuropharmacology 2011; 60: 295-302.
46. Song ZM, Undie AS, Koh PO, Fang YY, Zhang L, Dracheva S, Sealfon SC, Lidow MS: D 1 dopamine receptor regulation of microtubule- associated protein-2 phosphorylation in developing cerebral cortical neurons. J Neurosci 2002; 22: 6092-6105.
47. Stanwood GD, Levitt P: Drug exposure early in life: functional repercussions of changing neuropharmacology during sensitive periods of brain development. Curr Opin Pharmacol 2004; 4: 65-71.
48. Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, Caron MG: Local knockdown of genes in the brain using small interfering RNA: A phenotypic comparison with knockout animals. Biol Psychiatry 2007; 61: 65-69.
49. Cyr M, Beaulieu JM, Laakso A, Sotnikova TD, Yao WD, Bohn LM, Gainetdinov RR, Caron MG: Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci USA 2003; 100: 11035-11040.
50. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R: Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001; 98: 1982-1987.
51. Balci F, Ludvig EA, Abner R, Zhuang X, Poon P, Brunner D: Motivational effects on interval timing in dopamine transporter (DAT) knockdown mice. Brain Res 2010; 1325: 89- 99.
52. Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X: Hyperdopaminergic mutant mice have higher 'wanting' but not 'liking' for sweet rewards. J Neurosci 2003; 23: 9395- 9402.
53. Kim DS, Froelick GJ, Palmiter RD: Dopamine- dependent desensitization of dopaminergic signaling in the developing mouse striatum. J Neurosci 2002; 22: 9841-9849.
54. Zhou QY, Palmiter RD: Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995; 83: 1197-1209.